LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2

Int Immunopharmacol. 2012 Jul;13(3):225-31. doi: 10.1016/j.intimp.2012.04.008. Epub 2012 May 2.

Abstract

LPS inhalation was used to investigate whether sputum supernatant post-LPS challenge increases neutrophil chemotactic activity and to elucidate the role of CXCR1/CXCR2 signalling in this process. 14 healthy non-smoking subjects inhaled 30μg of LPS. Sputum was induced at baseline, 6 and 24h post-LPS challenge. Differential cell counts were determined and supernatants CXCL8, CXCL1, IL-6 and CCL2 levels measured. Peripheral blood neutrophils obtained from healthy volunteers were used for chemotaxis experiments using sputum supernatant. To delineate signalling mechanisms, the effects of a CXCR2/CXCR1 (dual) antagonist (Sch527123) and a CXCR2 specific antagonist (SB656933) were tested. LPS inhalation significantly increased sputum neutrophil counts from 45.3% to 76.7% and 69.3% at 6 and 24h respectively. LPS increased CXCL8, IL-6 and CCL2 levels but not CXCL1. Neutrophil chemotaxis significantly increased (2.7 fold) at 24h compared to baseline. Chemotaxis was inhibited by 79.0% with Sch527123 and 52.0% with SB656933. We conclude that LPS challenge increases sputum supernatant CXCL8 levels, which is associated with increased chemotactic activity which is dependent on both CXCR1 and CXCR2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adult
  • Benzamides / pharmacology
  • Chemokine CCL2 / metabolism
  • Chemotaxis, Leukocyte / drug effects
  • Chemotaxis, Leukocyte / immunology
  • Cyclobutanes / pharmacology
  • Female
  • Humans
  • Interleukin-6 / metabolism
  • Leukocyte Count
  • Lipopolysaccharides / administration & dosage*
  • Male
  • Models, Immunological
  • Neutrophils / drug effects*
  • Neutrophils / immunology*
  • Phenylurea Compounds / pharmacology
  • Receptors, Interleukin-8A / antagonists & inhibitors
  • Receptors, Interleukin-8A / metabolism*
  • Receptors, Interleukin-8B / antagonists & inhibitors
  • Receptors, Interleukin-8B / metabolism*
  • Sputum / cytology
  • Sputum / immunology
  • Sulfonamides / pharmacology

Substances

  • 2-hydroxy-N,N-dimethyl-3-(2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-enylamino)benzamide
  • Benzamides
  • CCL2 protein, human
  • Chemokine CCL2
  • Cyclobutanes
  • IL6 protein, human
  • Interleukin-6
  • Lipopolysaccharides
  • Phenylurea Compounds
  • Receptors, Interleukin-8A
  • Receptors, Interleukin-8B
  • SB 656933
  • Sulfonamides